江苏星盛新辉医药

Jiangsu Xingsheng Xinhui Pharmaceutical is a clinical-stage biotechnology company and a key research and development subsidiary of the CSPC Pharmaceutical Group. The company specializes in the discovery and development of innovative small molecule therapeutics, primarily targeting oncology and autoimmune indications. Its robust pipeline includes several first-in-class or best-in-class candidates, such as PRMT5 inhibitors, ATM inhibitors, and selective RET inhibitors, which are currently undergoing Phase 1 clinical evaluation. Xingsheng Xinhui leverages its parent company's extensive manufacturing and commercialization capabilities to accelerate the translation of its scientific discoveries into clinical treatments. The company is headquartered in Nanjing, Jiangsu, and represents a significant component of CSPC's strategy to expand its portfolio of innovative medicines.